The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Open accessAbstract
The cytotoxicity of paclitaxel against eight human tumour cell lines has been studied with in vitro clonogenic assays. The fraction of surviving cells fell sharply after exposure for 24 h to paclitaxel concentrations ranging from 2 to 20 nM; the paclitaxel IC50 was found to range between 2.5 and 7.5 nM. Increasing the paclitaxel concentration above 50 nM, however, resulted in no additional cytotoxicity after a 24 h drug exposure. Cells incubated in very high concentrations of paclitaxel (10,000 nM) had an increase in survival compared with cells treated with lower concentrations of the drug. Prolonging the time of exposure of cells to paclitaxel from 24 to 72 h increased cytotoxicity from 5 to 200 fold in different cell lines. Exponentially growing cells were more sensitive to paclitaxel than were cells in the plateau phase of growth. Cremophor EL, the diluent in which the clinical preparation of paclitaxel is formulated, antagonised paclitaxel at concentrations of 0.135% (v/v). These data suggest that paclitaxel will be most effective clinically when there is prolonged exposure of tumour to the drug. Further, it appears that modest concentrations (i.e., 50 nM) should be as effective as higher concentrations of paclitaxel. Finally, we have noted that Cremophor EL is a biologically active diluent and, at high concentrations (0.135% v/v), can antagonise paclitaxel cytotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 3,813
Self-citationPromotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,970
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Taxol: an antimitotic agent with a new mechanism of action
Manfredi, J. J., & Horwitz, S. B. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90025-1 · Cited by 483
Taxol: Mechanisms of Action and Resistancea
HORWITZ, S. B., LOTHSTEIN, L., MANFREDI, J. J., MELLADO, W., PARNESS, J., ROY, S. N., SCHIFF, P. B., SORBARA, L., & ZEHEB, R. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb38455.x · Cited by 416
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Rowinsky, E. K., Donehower, R. C., Jones, R. J., & Tucker, R. W. (1988) · PubMed · Cited by 368
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J. L., Rubin, S., Curtin, J., Barakat, R., & Phillips, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1485 · Cited by 313
Cited by
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.005 · Cited by 1,118
Naksuriya, O., Okonogi, S., Schiffelers, R. M., & Hennink, W. E. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.090 · Cited by 841
Fonseca, C., Simões, S., & Gaspar, R. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00212-2 · Cited by 755
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Anticancer Activity of Natural Compounds from Plant and Marine Environment
Lichota, A., & Gwozdzinski, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113533 · Cited by 473
Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy
Zhang, Y., Cai, K., Li, C., Guo, Q., Chen, Q., He, X., Liu, L., Zhang, Y., Lu, Y., Chen, X., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b05263 · Cited by 442
Spencer, C. M., & Faulds, D. (1994) · Drugs · doi:10.2165/00003495-199448050-00009 · Cited by 396
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules
Vigderman, L., & Zubarev, E. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.004 · Cited by 305
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., & Ozols, R. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1860 · Cited by 295
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway
Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D., & Lazarides, E. (1995) · Molecular Medicine · doi:10.1007/bf03401588 · Cited by 282
Zakharian, T. Y., Seryshev, A., Sitharaman, B., Gilbert, B. E., Knight, V., & Wilson, L. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0546525 · Cited by 277
Pharmacokinetic variability of anticancer agents
Undevia, S. D., Gomez-Abuin, G., & Ratain, M. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1629 · Cited by 258
A microengineered pathophysiological model of early-stage breast cancer
Choi, Y., Hyun, E., Seo, J., Blundell, C., Kim, H. C., Lee, E., Lee, S. H., Moon, A., Moon, W. K., & Huh, D. (2015) · Lab on a Chip · doi:10.1039/c5lc00514k · Cited by 222
Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V. (2020) · Science Advances · doi:10.1126/sciadv.aba5542 · Cited by 63
Ayalew, L., Acuna, J., Urfano, S. F., Morfin, C., Sablan, A., Oh, M., Gamboa, A., & Slowinska, K. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00117 · Cited by 35
Li, J., Li, Z., Li, M., Zhang, H., & Xie, Z. (2015) · Journal of Applied Polymer Science · doi:10.1002/app.41440 · Cited by 16
Metadata
- Authors
- Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J.
- Venue
- British Journal of Cancer
- Published
- 1993-12
- Volume
- 68
- Issue
- 6
- Pages
- 1104-1109
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2075960393
- Cited by
- 428
- References
- 17
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.